# Genevant Sciences

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/genevant-sciences
Canonical HTML page: https://gethealthbrief.com/entity/genevant-sciences

## Recent coverage (1 stories)

### Moderna Settles mRNA Patent Dispute with Roivant for Up to $2.25 Billion
2026-03-04 14:38:26 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Moderna has agreed to pay Roivant Sciences up to $2.25 billion to settle long-standing patent infringement claims regarding the Lipid Nanoparticle (LNP) technology used in its COVID-19 vaccine. The settlement provides a massive capital windfall for Roivant and Arbutus Biopharma while removing a major legal risk for Moderna.
Full story: https://gethealthbrief.com/story/moderna-roivant-mrna-patent-settlement

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.